These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 24842649)
1. Duloxetine-bupropion combination for treatment-resistant atypical depression: a double-blind, randomized, placebo-controlled trial. Fornaro M; Martino M; Mattei C; Prestia D; Vinciguerra V; De Berardis D; De Pasquale C; Iasevoli F; Mungo S; Fornaro P Eur Neuropsychopharmacol; 2014 Aug; 24(8):1269-78. PubMed ID: 24842649 [TBL] [Abstract][Full Text] [Related]
2. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385 [TBL] [Abstract][Full Text] [Related]
3. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression. Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348 [TBL] [Abstract][Full Text] [Related]
4. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901 [TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831 [TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Katona C; Hansen T; Olsen CK Int Clin Psychopharmacol; 2012 Jul; 27(4):215-23. PubMed ID: 22572889 [TBL] [Abstract][Full Text] [Related]
7. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Baldwin DS; Loft H; Dragheim M Eur Neuropsychopharmacol; 2012 Jul; 22(7):482-91. PubMed ID: 22209361 [TBL] [Abstract][Full Text] [Related]
8. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder. Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729 [TBL] [Abstract][Full Text] [Related]
9. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation. Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641 [TBL] [Abstract][Full Text] [Related]
10. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695 [TBL] [Abstract][Full Text] [Related]
11. The combination of duloxetine and bupropion for treatment-resistant major depressive disorder. Papakostas GI; Worthington JJ; Iosifescu DV; Kinrys G; Burns AM; Fisher LB; Homberger CH; Mischoulon D; Fava M Depress Anxiety; 2006; 23(3):178-81. PubMed ID: 16528701 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Raskin J; Wiltse CG; Siegal A; Sheikh J; Xu J; Dinkel JJ; Rotz BT; Mohs RC Am J Psychiatry; 2007 Jun; 164(6):900-9. PubMed ID: 17541049 [TBL] [Abstract][Full Text] [Related]
13. St. John's wort extract LI160 for the treatment of depression with atypical features - a double-blind, randomized, and placebo-controlled trial. Mannel M; Kuhn U; Schmidt U; Ploch M; Murck H J Psychiatr Res; 2010 Sep; 44(12):760-7. PubMed ID: 20181361 [TBL] [Abstract][Full Text] [Related]
14. Acute and long-term treatment of late-life major depressive disorder: duloxetine versus placebo. Robinson M; Oakes TM; Raskin J; Liu P; Shoemaker S; Nelson JC Am J Geriatr Psychiatry; 2014 Jan; 22(1):34-45. PubMed ID: 24314888 [TBL] [Abstract][Full Text] [Related]
15. BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine. Ninan PT; Shelton RC; Bao W; Guico-Pabia CJ Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():86-91. PubMed ID: 24096053 [TBL] [Abstract][Full Text] [Related]
16. Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression. Shelton RC; Prakash A; Mallinckrodt CH; Wohlreich MM; Raskin J; Robinson MJ; Detke MJ Int J Clin Pract; 2007 Aug; 61(8):1337-48. PubMed ID: 17627710 [TBL] [Abstract][Full Text] [Related]
18. Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic features. Mallinckrodt CH; Watkin JG; Liu C; Wohlreich MM; Raskin J BMC Psychiatry; 2005 Jan; 5():1. PubMed ID: 15631624 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial. Brecht S; Desaiah D; Marechal ES; Santini AM; Podhorna J; Guelfi JD J Clin Psychiatry; 2011 Aug; 72(8):1086-94. PubMed ID: 20868642 [TBL] [Abstract][Full Text] [Related]
20. An open-label, rater-blinded, 8-week trial of bupropion hydrochloride extended-release in patients with major depressive disorder with atypical features. Seo HJ; Lee BC; Seok JH; Jeon HJ; Paik JW; Kim W; Kwak KP; Han C; Lee KU; Pae CU Pharmacopsychiatry; 2013 Sep; 46(6):221-6. PubMed ID: 23963965 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]